Toward precision medicine in glioblastoma: the promise and the challenges
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Toward precision medicine in glioblastoma: the promise and the challenges
Authors
Keywords
-
Journal
NEURO-ONCOLOGY
Volume 17, Issue 8, Pages 1051-1063
Publisher
Oxford University Press (OUP)
Online
2015-05-02
DOI
10.1093/neuonc/nov031
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intravenous delivery of camptothecin-loaded PLGA nanoparticles for the treatment of intracranial glioma
- (2015) Kyle T. Householder et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
- (2015) J. Schuster et al. NEURO-ONCOLOGY
- Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity
- (2015) Mona Meyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Beta-Blocker Drug Therapy Reduces Secondary Cancer Formation in Breast Cancer and Improves Cancer Specific Survival
- (2015) Oncotarget
- Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide
- (2015) Joanna Triscott et al. Oncotarget
- High-Throughput Chemical Screens Identify Disulfiram as an Inhibitor of Human Glioblastoma Stem Cells
- (2015) Parvinder Hothi et al. Oncotarget
- Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma
- (2015) Jennifer K Wolter et al. Oncotarget
- A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.
- (2015) Richard E. Kast et al. Oncotarget
- CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide
- (2015) Richard E. Kast et al. Oncotarget
- Medical treatment of orthotopic glioblastoma with transferrin-conjugated nanoparticles encapsulating zoledronic acid
- (2015) Manuela Porru et al. Oncotarget
- Redox-Responsive Magnetic Nanoparticle for Targeted Convection-Enhanced Delivery of O6-Benzylguanine to Brain Tumors
- (2014) Zachary R. Stephen et al. ACS Nano
- Drug and cell encapsulation: Alternative delivery options for the treatment of malignant brain tumors
- (2014) Swapnil V. Bhujbal et al. ADVANCED DRUG DELIVERY REVIEWS
- A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme
- (2014) Myrna R Rosenfeld et al. Autophagy
- Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy
- (2014) Giles W Robinson et al. BMC CANCER
- Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384
- (2014) Yanni Zhu et al. CANCER BIOLOGY & THERAPY
- Autologous T-cell Therapy for Cytomegalovirus as a Consolidative Treatment for Recurrent Glioblastoma
- (2014) A. Schuessler et al. CANCER RESEARCH
- Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses
- (2014) A.-M. Tsimberidou et al. CLINICAL CANCER RESEARCH
- Functional Kinomics Identifies Candidate Therapeutic Targets in Head and Neck Cancer
- (2014) R. Moser et al. CLINICAL CANCER RESEARCH
- Epidermal growth factor receptor endocytic traffic perturbation by phosphatidate phosphohydrolase inhibition: new strategy against cancer
- (2014) Ronan Shaughnessy et al. FEBS Journal
- Functional Nanoparticles in Targeting Glioma Diagnosis and Therapies
- (2014) Minghui Li et al. JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY
- Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma
- (2014) Eiichi Ishikawa et al. JOURNAL OF NEUROSURGERY
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
- (2014) Roger Stupp et al. LANCET ONCOLOGY
- Standardized decision support in next generation sequencing reports of somatic cancer variants
- (2014) Rodrigo Dienstmann et al. Molecular Oncology
- A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
- (2014) Daniel J. Ma et al. NEURO-ONCOLOGY
- Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
- (2014) P. Y. Wen et al. NEURO-ONCOLOGY
- A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
- (2014) Mark R. Gilbert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- (2014) Olivier L. Chinot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combining Microbubbles and Ultrasound for Drug Delivery to Brain Tumors: Current Progress and Overview
- (2014) Hao-Li Liu et al. Theranostics
- Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
- (2014) Filip Janku et al. Cell Reports
- The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy
- (2014) Mira Patel et al. Cancers
- Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage
- (2013) A. Paranjpe et al. CARCINOGENESIS
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Improving the prediction of drug disposition in the brain
- (2013) Kiril Lanevskij et al. Expert Opinion on Drug Metabolism & Toxicology
- How could a drug used to treat alcoholism also be effective against glioblastoma?
- (2013) Weiguang Wang et al. Expert Review of Anticancer Therapy
- Loss of Tsc1 accelerates malignant gliomagenesis when combined with oncogenic signals
- (2013) Daisuke Yamada et al. JOURNAL OF BIOCHEMISTRY
- Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer
- (2013) Peter Nygren et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Brainstem Ganglioglioma Successfully Treated With Vemurafenib
- (2013) Sarah Rush et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry
- (2013) Oscar Gallego et al. JOURNAL OF NEURO-ONCOLOGY
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
- (2013) F Traina et al. LEUKEMIA
- Contribution of ATM and ATR to the Resistance of Glioblastoma and Malignant Melanoma Cells to the Methylating Anticancer Drug Temozolomide
- (2013) Marcus Eich et al. MOLECULAR CANCER THERAPEUTICS
- The integrated landscape of driver genomic alterations in glioblastoma
- (2013) Veronique Frattini et al. NATURE GENETICS
- Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110
- (2013) A. Schulte et al. NEURO-ONCOLOGY
- Epidermal Growth Factor Receptor as a Therapeutic Target in Glioblastoma
- (2013) B. Kalman et al. NEUROMOLECULAR MEDICINE
- PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations
- (2013) A I Velghe et al. ONCOGENE
- Combined RNAi-Mediated Suppression of Rictor and EGFR Resulted in Complete Tumor Regression in an Orthotopic Glioblastoma Tumor Model
- (2013) Maite Verreault et al. PLoS One
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
- (2013) A. Sottoriva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition
- (2013) N. Wagle et al. Cancer Discovery
- Formulations for Intranasal Delivery of Pharmacological Agents to Combat Brain Disease: A New Opportunity to Tackle GBM?
- (2013) Matthias van Woensel et al. Cancers
- Targeting SMARCAL1 as a novel strategy for cancer therapy
- (2012) Lu Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors
- (2012) Maja T. Tomicic et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors
- (2012) Peter E. Zage et al. CANCER
- Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
- (2012) Hilko Ardon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy
- (2012) Ankita Thakur et al. CANCER LETTERS
- Receptor Tyrosine Kinase Genes Amplified in Glioblastoma Exhibit a Mutual Exclusivity in Variable Proportions Reflective of Individual Tumor Heterogeneity
- (2012) S. E. Little et al. CANCER RESEARCH
- Abstract 3350: Implications of the STAT6 pathway by interleukin-4 in prostate cancer
- (2012) Holger H. Erb et al. CANCER RESEARCH
- PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
- (2012) F. Janku et al. CANCER RESEARCH
- Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner
- (2012) J. S. Khalili et al. CLINICAL CANCER RESEARCH
- New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: A pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials
- (2012) Thierry Gorlia et al. EUROPEAN JOURNAL OF CANCER
- Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors
- (2012) Mukul Minocha et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer
- (2012) Kang-Yi Su et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial
- (2012) David Neal Franz et al. LANCET
- Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models
- (2012) J. M. Gozgit et al. MOLECULAR CANCER THERAPEUTICS
- Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02
- (2012) E. Q. Lee et al. NEURO-ONCOLOGY
- Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006
- (2012) K. R. Yabroff et al. NEURO-ONCOLOGY
- p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
- (2012) L. Cen et al. NEURO-ONCOLOGY
- A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme
- (2012) Pål A. Rønning et al. NEURO-ONCOLOGY
- Targeting DNA repair mechanisms in cancer
- (2012) John M. Furgason et al. PHARMACOLOGY & THERAPEUTICS
- Loss of Atrx Sensitizes Cells to DNA Damaging Agents through p53-Mediated Death Pathways
- (2012) Damiano Conte et al. PLoS One
- Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response
- (2012) N. J. Szerlip et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
- (2012) D. Singh et al. SCIENCE
- Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors
- (2012) Igor Vivanco et al. Cancer Discovery
- Current concepts and management of glioblastoma
- (2011) Matthias Preusser et al. ANNALS OF NEUROLOGY
- Mosaic Amplification of Multiple Receptor Tyrosine Kinase Genes in Glioblastoma
- (2011) Matija Snuderl et al. CANCER CELL
- Targeted Therapy for BRAFV600E Malignant Astrocytoma
- (2011) T. P. Nicolaides et al. CLINICAL CANCER RESEARCH
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Rapid Radiographic and Clinical Improvement After Treatment of a MET-Amplified Recurrent Glioblastoma With a Mesenchymal-Epithelial Transition Inhibitor
- (2011) Andrew S. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy
- (2011) Camilo E. Fadul et al. JOURNAL OF IMMUNOTHERAPY
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
- (2011) F. Janku et al. MOLECULAR CANCER THERAPEUTICS
- Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
- (2011) Martin D. Forster et al. Nature Reviews Clinical Oncology
- Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
- (2011) Ren-Yuan Bai et al. NEURO-ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Moving beyond Rules: The Development of a Central Nervous System Multiparameter Optimization (CNS MPO) Approach To Enable Alignment of Druglike Properties
- (2010) Travis T. Wager et al. ACS Chemical Neuroscience
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
- (2010) Houtan Noushmehr et al. CANCER CELL
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- Combination of Temsirolimus (CCI-779) with Chemoradiation in Newly Diagnosed Glioblastoma Multiforme (GBM) (NCCTG trial N027D) Is Associated with Increased Infectious Risks
- (2010) J. N. Sarkaria et al. CLINICAL CANCER RESEARCH
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma
- (2010) John H. Sampson et al. JOURNAL OF CLINICAL ONCOLOGY
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
- (2010) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- The molecular genetics underlying basal cell carcinoma pathogenesis and links to targeted therapeutics
- (2010) Julie K. Iwasaki et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease
- (2010) Jonathan H Fox et al. Molecular Neurodegeneration
- Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
- (2010) J. H. Sampson et al. NEURO-ONCOLOGY
- KIAA1018/FAN1 nuclease protects cells against genomic instability induced by interstrand cross-linking agents
- (2010) K. Yoshikiyo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors
- (2010) Andrew J. Sawyer et al. Drug Delivery and Translational Research
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
- (2009) Roger Stupp et al. LANCET ONCOLOGY
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- TORC1 Is Essential for NF1-Associated Malignancies
- (2008) Cory M. Johannessen et al. CURRENT BIOLOGY
- Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
- (2008) Monika E. Hegi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
- (2008) Teri N. Kreisl et al. JOURNAL OF CLINICAL ONCOLOGY
- A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM)
- (2008) Teri N. Kreisl et al. JOURNAL OF NEURO-ONCOLOGY
- Response of a Neuronal Model of Tuberous Sclerosis to Mammalian Target of Rapamycin (mTOR) Inhibitors: Effects on mTORC1 and Akt Signaling Lead to Improved Survival and Function
- (2008) L. Meikle et al. JOURNAL OF NEUROSCIENCE
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
- (2008) Kathleen R. Lamborn et al. NEURO-ONCOLOGY
- Experience with irinotecan for the treatment of malignant glioma
- (2008) James J. Vredenburgh et al. NEURO-ONCOLOGY
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
- Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma
- (2008) Tim F Cloughesy et al. PLOS MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now